A Phase 2 interventional study of SYH2069 Injection and SYH2069 Injection Placebo in Overweight or Obesity, sponsored by CSPC Ouyi Pharmaceutical Co., Ltd.. Not yet recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-04.
Sponsored by CSPC Ouyi Pharmaceutical Co., Ltd. (part of CSPC Pharmaceutical Group Limited) · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 600 studies in Obesity with a site in China — 221 open to participants now, 282 under way, 67 of them phase 3. Obesity · China.
Among the 600 studies in Obesity with a site in China, this one is the 107th largest by planned enrollment of the 502 interventional ones that give a count, is one of 134 that started in 2026, is one of 52 in phase 2, reaches primary completion later than 187 of the 280 other live ones, and was the 549th registered.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
Browse Obesity studies →221 of the 600 studies in Obesity with a site in China are open now. Recruiting first, the newest first:
Chendu DIAO Pharmaceutical Group CO., LTD. · Sites in China
Ages 18–65
The First Hospital of Jilin University · Sites in China
Ages 18–65
Pfizer · Sites in China
Ages 18+
Eli Lilly and Company · Sites in China, United States, Brazil and 7 more countries
Ages 18+
The United Bio-Technology (Hengqin) Co., Ltd. · Sites in China
Ages 18–55
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 1,342 Obesity studies recruiting now, 377 (28%) set no upper age limit and 861 (64%) stop at 75 or younger; 168 take children under 18; 489 take healthy volunteers.
This study: 18 Years to 65 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
600 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 103 · Phase 2 70 · Phase 3 108 · Phase 4 28
First in 1997; this study’s year is marked. 134 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 360 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Median enrollment 120 across the 502 interventional studies, 310 across the 98 observational. Of the 241 that completed or were terminated, 13 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
241 of 600 have an industry lead sponsor. The 10 most frequent:
This study is registered under CSPC Ouyi Pharmaceutical Co., Ltd., one of the names counted as CSPC Pharmaceutical Group Limited. Under that name alone:
CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
CSPC Pharmaceutical Group Limited has 9 studies filed under Obesity — fewer than ten, so there is no comparison to draw.
104 of the studies in Obesity with a site in China that are under way reach primary completion within a year, 20 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06974851Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity | 2026-12 |
| NCT06994650Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep Apnea (OSA) and Obesity Who Are on Positive Airway Pressure Ventilation (PAP) Therapy | 2026-12 |
| NCT06672549Phase 3Eli Lilly and CompanyA Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040) | 2027-02 |
| NCT07481747Phase 3Hudson BiotechEfficacy and Safety of Tirzepatide Once Weekly Versus Placebo in Participants Who Are Either Obese or Overweight With Weight-Related Comorbidities (SURMOUNT-1) | 2027-02-14 |
| NCT07285902Phase 3Fujian Shengdi Pharmaceutical Co., Ltd.A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obesity | 2027-03 |
Add all 104 to your calendar (.ics) → With an account.
Among the 600 studies in Obesity with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
To evaluate the efficacy and safety of SYH2069 injection compared with placebo in obese Non-diabetic Participants after 28 weeks of treatment.
11,543 studies on the registry are indexed under Obesity; 2,047 are open to participants now.
This study's planned enrollment of 360 is above the median of 67 across 9,023 interventional studies indexed under Obesity.
Browse Obesity studies →CSPC Ouyi Pharmaceutical Co., Ltd. is the lead sponsor of 30 studies on the registry; 15 are open to participants now.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Overweight. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
SYH2069 dose 1 : SYH2069 Injection: dose level 1 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 2: SYH2069 Injection: dose level 2 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 3: SYH2069 Injection: dose level 3 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 4: SYH2069 Injection: dose level 4 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 5: SYH2069 Injection: dose level 5 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 6: SYH2069 Injection: dose level 6 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 7: SYH2069 Injection: dose level 7 for 28 weeks
Drug: SYH2069 Injection
SYH2069 dose 8: SYH2069 Injection: dose level 8 for 28 weeks
Drug: SYH2069 Injection
SYH2069 Injection Placebo: Placebo arm matching active arm SYH2069 Injection dose level for 28 weeks
Drug: SYH2069 Injection Placebo
0.6ml , 1.2ml , administered subcutaneously (SC),Administer the drug according to the clinical trial protocol
0.6ml , 1.2ml , SC,Administer the drug according to the clinical trial protocol
Relative percentage change in body weight from baseline at of treatment at 28 weeks of treatment
Time frame: 28 weeks
Proportion of subjects with a weight loss of ≥5% , 10%, 15% from baseline at 28 weeks of treatment
Time frame: Baseline through Week 28
Change from baseline in body Weight
Time frame: Week 2, 4, 8, 12, 16, 20, 24 and 28
Changes from baseline in waist circumference
Time frame: Baseline through Week 28
Changes from baseline in hip circumference
Time frame: Baseline through Week 28
Changes from baseline in waist-to-hip ratio
Time frame: Baseline through Week 28
Changes from baseline in Body Mass Index (BMI)
Time frame: Baseline through Week 28
Changes from baseline in Hemoglobin A1c (HbA1c)
Time frame: Baseline through Week 28
Changes from baseline in fasting plasma glucose (FPG)
Time frame: Baseline through Week 28
Changes from baseline in fasting C-peptide
Time frame: Baseline through Week 28
Changes from baseline in Homeostatic Model Assessment of Insulin Resistance(HOMA-IRs)
Time frame: Baseline through Week 28
Changes from baseline in systolic blood pressure
Time frame: Baseline through Week 28
Changes from baseline in diastolic blood pressure
Time frame: Baseline through Week 28
Changes from baseline in lipid parameters (TC, LDL-C, HDL-C, non-HDL-C, TG, ApoB)
Time frame: Baseline through Week 28
Changes from baseline in high sensitivity C reactive protein (hs-CRP)
Time frame: Baseline through Week 28
Changes from baseline in urinary albumin-to-creatinine ratio (UACR)
Time frame: Baseline through Week 28
The incidence rate of adverse events (AEs)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Peak Time (Tmax)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Peak Plasma Concentration (Cmax)
Time frame: Baseline through Week 31
Plasma concentrations & PK parameters: Area under the plasma concentration versus time curve(AUC) : AUClast, AUC0-168h, AUC0-336h
Time frame: Baseline through Week 31
Start is estimated for Sep 2026; primary completion for Sep 2027, 12 months later.
Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's planned 12 months is close to that.
Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: SYH2069
CSPC Ouyi Pharmaceutical Co., Ltd. →